Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antipsychotic agents and the future.

A V Mackay

    The Journal of Clinical Psychiatry
    |April 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Future antipsychotic drug design may require novel approaches beyond dopamine antagonism, focusing on clinical use optimization and treating schizophrenia

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics.

    British journal of clinical pharmacology·2012
    Same author

    Concept of disease in psychiatry.

    Journal of the Royal Society of Medicine·2010
    Same author

    Psychiatric research.

    Journal of the Royal Society of Medicine·2010
    Same author

    Schizophrenia as failure of hemispheric dominance for language.

    Trends in neurosciences·1998
    Same author

    Issues in drug treatment for Alzheimer's disease.

    Lancet (London, England)·1997
    Same author

    A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.

    British journal of clinical pharmacology·1996

    Area of Science:

    • Neuropharmacology
    • Psychiatry

    Background:

    • Antipsychotic drug development currently lacks etiological understanding and adequate animal models for target diseases.
    • Dopamine receptor antagonism is a validated predictor of antipsychotic efficacy.

    Purpose of the Study:

    • To explore future directions in antipsychotic agent design.
    • To address limitations of current receptor-active drugs and clinical challenges in schizophrenia treatment.

    Main Methods:

    • Pragmatic extension of existing drug knowledge.
    • Analysis of dopamine receptor antagonism as a predictor.
    • Consideration of receptor number changes.
    • Exploration of non-receptor-active neuroleptic alternatives.

    Main Results:

    Related Experiment Videos

    • Further gains from selective dopamine antagonists may be limited.
    • Reactive changes in receptor numbers pose a challenge for receptor-active drugs.
    • Lithium's non-receptor-mediated action offers a potential model for maintenance therapy.

    Conclusions:

    • Future antipsychotic design may need to move beyond solely dopamine antagonism.
    • Optimizing clinical dosage and duration is crucial.
    • Developing treatments for the schizophrenic defect state remains a priority.